PIONEERING TEAM OF VIROLOGISTS BASED IN UNIVERSITY OF BIRMINGHAM
By MYLES BUCHANAN
Wednesday February 01 2012
A DOCTOR FROM Roundwood is leading pioneering research into Hepatitis C.
Dr. Nicola Fletcher is the head of a team of virologists from the University of Birmingham who found that the endothelial cells in the brain possess the four main protein receptors necessary for the blood-brain barrier to be targeted by HCV.
The findings, which are published in Research Highlights in the journal Nature Reviews Gastroenterology and Hepatology, show that cells other than liver hepatocytes can be vulnerable to HCV infection.
Hepatitis C virus (HCV) is an RNA virus of the Flaviviridae family that poses a global health problem. Infection leads to progressive liver disease and has been associated with a variety of extrahepatic syndromes, including central nervous system (CNS) abnormalities.
Working with the Manhattan Brain Bank in New York, USA, the researchers, led by Dr. Fletcher, of the University's School of Immunity and Infection, detected HCV genomic material in the brains of four out of ten infected patients who posthumously donated brain and liver tissue.
The team went on to demonstrate in laboratory tests that brain cells isolated from the blood-brain barrier could be infected with HCV.
' This is the first report that cells of the central nervous system support HCV replication,' says corresponding author Professor Jane Mckeating, chair of molecular virology at the University of Birmingham. ' These observations could have clinical implications providing a reservoir for the virus to persist during antiviral treatment'
Dr. Fletcher was educated in St David' Secondary School in Greystones, University of Limerick, and UCD where she completed her PHD before moving to the University of Birmingham to progress her research into the Hepatitis C virus.
Speaking about the findings, she says, ' The endothelial cells make up the security system of the brain, a kind of bouncer at the door that keeps out undesirable elements. If this barrier is compromised all kinds of substances can gain access to the brain, which may explain the fatigue and other symptoms reported by Hcv-infected patients.'
The current standard of care for treating Hcv-infected patients is only partially effective, she says, so there is a considerable drive to develop agents that target viral specific enzymes as alternative therapies. 'We anticipate that such agents will be less able to cross the bloodbrain barrier compared to existing drugs. We believe our data provides a detailed mechanistic view of how an infectious agent can target the brain.' Dr. Fletcher's other passion in life in the UK is her award-winning flock of pedigree Jacob Sheep appropriately called the 'Sugarloaf Jacob Flock' which she keeps at her home in Roundwood.
- MYLES BUCHANAN
No comments:
Post a Comment